No validated diagnostic test for MCS exists. That is a fact about the research, not about the illness. Dozens of candidate markers have been studied; none has been shown to separate MCS from controls reliably enough to diagnose an individual. Producing one is a central research goal, and it is more likely to come from a systems profile than from a single blood test.
Diagnosis today rests on history and the consensus criteria, supported by the QEESI questionnaire. Capsaicin challenge, imaging and inflammatory markers show group differences; none is specific enough for one patient. Standard allergy testing is normal because MCS is not IgE-mediated.
A large evidence-mapping project at the University of Southern California and Johns Hopkins has cataloged more than 350 eligible MCS studies, including dozens on proposed diagnostic tests, and reports that no accepted biomarker has emerged. Thirty years of looking for one marker has not found it.
The likely reason is that MCS involves several systems at once — sensory receptors, central processing, autonomic regulation, mast cells, inflammation — and no single one carries the whole signal. Conditions like that get diagnosed by profile: fibromyalgia by criteria plus exclusion, POTS by a tilt test, small-fiber neuropathy by biopsy. MCS may need a panel: sensory threshold, sudomotor testing, autonomic response, mast-cell markers, and a standardized challenge.
That panel does not exist because nobody has measured all of those systems in the same well-characterized patients against matched controls. Doing that is the second phase of the registry’s research program.
Recruiting characterized subgroups for systems-level measurement rather than another single-marker study, and recording which objective findings participants already have on file.
There is no test for MCS yet. The condition is real without one, and the path to one runs through measuring several systems in the same people, which is what the research program is built to do.